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Available online 21 June 2019High-mobility Group Box 1 (HMGB1) is an abundant protein present in all mammalian cells and involved in sev-
eral processes. During inﬂammation or tissue damage, HMGB1 is released in the extracellular space and, depend-
ing on its redox state, can form a heterocomplex with CXCL12. The heterocomplex acts exclusively via the
chemokine receptor CXCR4 enhancing leukocyte recruitment.
Here, we used multi-microsecond molecular dynamics (MD) simulations to elucidate the effect of the disulﬁde
bond on the structure and dynamics of HMGB1.
The results of theMD simulations show that the presence or lack of the disulﬁde bond between Cys23 and Cys45
modulates the conformational space explored by HMGB1, making the reduced protein more suitable to form a
complex with CXCL12.
© 2019 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and Structural
Biotechnology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Keywords:
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High-mobility Group Box 1 (HMGB1) is an abundant chromatin-
associated protein present in all mammalian cells. It is formed by 215
amino acids, divided into two domains, “BoxA” (Gly2-Ile79) and
“BoxB” (Phe89-Arg163), connected by a nine amino acid loop, and a
highly disordered negatively charged C-terminal tail.
BoxA contains a pair of cysteines (Cys23 and Cys45) that can form a
disulﬁde bond under oxidative conditions. In contrast, only one un-
paired cysteine is present in BoxB (Cys106, Fig. 1A) [1,2].fr-HMGB1, Full reduced High-
ty Group Box 1; CXCL12, C-X-C
type 4; TLR2 or TLR4, Toll-like
mean square deviation; SASA,
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c-nd/4.0/).The three domains of HMGB1 play a key role in establishing and reg-
ulating its wide interactome [3,4], as well as, in the modulation of the
protein conformation [5].
Depending on its cellular localization, HMGB1 performs different
functions. In fact, as a nuclear protein, it is involved in DNA repair, tran-
scription, telomere maintenance, and genome stability [2,6,7], while
during cellular death or inﬂammation, HMGB1 is released in the extra-
cellular space where it functions as an alarmin [8,9].
According to multiple studies, several HMGB1 functions depend on
its redox states [10,11].
The nuclear and cytosolic environments are characterized by a neg-
ative redox potential that maintains HMGB1 in reduced form (fr-
HMGB1). During an inﬂammatory process, the extracellular space,
enriched in reactive oxygen species, lead to the formation of a disulﬁde
bond between cysteines at positions 23 and 45 of BoxA (ds-HMGB1)
[12]. ds-HMGB1 activates Toll-like Receptor 2 (TLR2) and 4 (TLR4)
inducing the release of proinﬂammatory chemokines and cytokines ac-
tivating innate and adaptive immune responses. On the contrary, fr-
HMGB1 binds to the receptor for advanced glycation end products
(RAGE), modulating autophagy [9,13,14].
The CXC ligand 12 (CXCL12) is expressed inmany tissues both under
homeostatic and inﬂammatory conditions and can stimulate cellular re-
cruitment by activating the CXC chemokine receptor type 4 (CXCR4)mputational and Structural Biotechnology. This is an open access article under the CC BY-
Table 1
Summary of the MD simulations performed in this study.
System Description Simulation
Time
fr-HMGB1 HMGB1 NMR structure (PDB ID code 2YRQ) 30 × 1 μs
ds-HMGB1 HMGB1 with a disulﬁde bond between Cys23-Cys45 30 × 1 μs
fr-HMGB1(I) First representative cluster of the fr-HMGB1 +
CXCL122 complex
3 × 500 ns
fr-HMGB1(II) The second representative cluster of the fr-HMGB1
+ CXCL122 complex
3 × 500 ns
ds-HMGB1(II) The second representative cluster of the ds-HMGB1
+ CXCL122 complex
3 × 500 ns
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HMGB1 heterocomplex enhanced the activities of CXCR4 in human
monocytes [16]. In particular, a suboptimal concentration of CXCL12,
which per se would not trigger any chemotactic response, efﬁciently
promotes migration of humanmonocytes, by forming a heterocomplex
with fr-HMGB1 [16,17]. More recently, other studies demonstrated the
important role of the heterocomplex in tissue regeneration [13,18,19]
and in fueling the inﬂammatory response in patients with Rheumatoid
Arthritis [20].
A particular feature of the CXCL12/HMGB1 heterocomplex is that
only fr-HMGB1 can complex with CXCL12, promoting CXCR4-induced
response [17]. This appears contradictory because the extracellular
space, where the heterocomplex is formed, is rich in reactive oxidative
species [17]. However, under speciﬁc conditions, cells can release gluta-
thione reductase and enzymes of the thioredoxin system to counteract
the oxidative stress in the microenvironment, contributing to maintain
HMGB1 in the reduced state [20,21].
While a structure of the heterocomplex is currently unavailable,
NMR chemical shift mapping clearly showed an interaction between
CXCL12 and the two domains of HMGB1 (BoxA and BoxB), separately
[16]. Furthermore, the same experiments showed that the binding of
CXCL12 to HMGB1 induces conformational changes in the N-terminalFig. 1. (A) Structure of HMGB1 (PDB ID code 2YRQ) solved by NMR. Protein domains are
presented in different colors: BoxA (red), BoxB (blue), and the loop between the two
domains (green). The three cysteines located at positions 23 and 45 in BoxA and 106 in
BoxB are displayed as van der Waals balls in different colors. (B) Explicative
representation, of the binding of the CXCL122/HMGB1 to a CXCR4 dimer. HMGB1 is
depicted in aquamarine, the two CXCL12 in green, while the two CXCR4 monomers in
blue and red respectively.domain of CXCL12 which is required to trigger the activation of the re-
ceptor. Based on these data, itwashypothesized that theheterocomplex
is formed by two CXCL12 molecules bound to fr-HMGB1 (one to BoxA
and one to BoxB), and that it would bind CXCR4 dimers (Fig. 1B) [16].
In this study, aiming to validate the assumed mode of action of the
heterocomplex, we applied several molecular modeling techniques,
such as molecular dynamics (MD) simulations and protein-protein
docking, to investigate which structural and/or conformational differ-
ences between the two redox states of HMGB1 could explain the differ-
ent afﬁnity of fr- and ds-HMGB1 for CXCL12.
According to our ﬁndings, ds-HMGB1 tends to bemore compact and
displays a lower accessible surface than fr-HMGB1, while the structure
of BoxA remains essentially unchanged in the two states. Furthermore,
in-depth analysis of the simulations and the results of protein-protein
docking calculations showed that the vast majority of the conforma-
tions assumed by fr-HMGB1 are able to bind two CXCL12 molecules
with an orientation and distance optimal to trigger the activation of
CXCR4 dimers. We, therefore, propose that functional differences be-
tween fr- and ds-HMGB1 are at least partially caused by global changes
in the conﬁgurational landscape of HMGB1.
2. Methods
The afﬁnity of the CXCL12/HMGB1 heterocomplex was measured
by microscale thermophoresis (MST) [22,23]. Brieﬂy, 100 nM
HMGB1-His tagged, either reduced or oxidized, was labelled with
100 μM Monolith NTTM His-Tag Labeling kit RED-tris-NTA (L008,
NANOTEMPER, Munich, Germany) 30 min at room temperature
(RT) in the dark, and centrifuged (14.000 rpm; 10 min; 4 °C) to dis-
card the excess of dye in the tube. Labelled HMGB1 was used at ﬁnal
concentration of 10 nM in the presence of different doses of CXCL12,
prepared performing 16 serial dilutions from the initial concentra-
tion of 14 μM according to the manufacturer instructions. Dilution
buffer was obtained by mixing 20 mM NaCl/NaH2PO4 pH 6.0 and
PBS 0.1% Tween 20 pH 7.4 at 1:1 ratio.
Measurementswere performed using theMonolithNT.115MSTPre-
mium Coated Capillaries (K005, NANOTEMPER, Munich, Germany), ex-
citation Power 20%,MST powermedium,with theMonolithNT.115 Pico
instrument (NANOTEMPER, Munich, Germany).
Apparent Kd values were computed ﬁtting the compound
concentration-dependent changes in normalized ﬂuorescenceTable 2
Residues involved in the interaction between HMGB1 and CXCL12 used to drive the
docking procedure.
Residues of HMGB1 interacting with CXCL12
BoxA 14S, 16Y, 17A, 20V, 24R, 25E, 38F, 39S, 50K, 57K
BoxB 96K, 103F, 104L, 113I, 114K, 115G, 116E, 120L, 137A, 155Y, 158D
Residues of CXCL12 interacting with HMGB1
With
BoxA
18V, 19A, 23V, 24K, 25H, 38I, 40A, 41R, 42L, 44N, 48Q, 59N, 64K
With
BoxB
15E, 18V, 20R, 23V, 24K, 38I, 40A, 41R, 45N, 51I, 57W, 58I, 59N, 64K,
65A, 66L
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Fig. 2. MST curve of CXCL12 titrated into labelled fr-HMGB1 (A) and ds-HMGB1 (B). (C) Histograms of the radius of gyration (RoG) and (D) solvent accessible surface area (SASA)
computed using all residues of the protein. Details about the Phe38 orientation in the ds- (E, pdb code 2RTU) and fr- (F, 2YRQ) HMGB1. Histograms of the distance between the center
of mass (COM) of Phe38 and COM of Val20 (G), Gln21 (H) and Arg24 (I). In all histograms, the data for fr-HMGB1 are shown in blue while those of ds-HMGB1 in red.
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Final results were obtained averaging four independent experiments.
Both CXCL12 and HMGB1 were prepared as in ref. [20]. Oxidized
HMGB1was obtained after sample dialysis, to removeDTT, and incubat-
ing the protein over night at room temperature to allow spontaneous
oxidation.2.1. Systems Setup and MD Simulations
MD simulations are powerful tools already applied to the study of
some mechanistic aspects of the HMGB1 cellular functions [24,25].
In this case, the HMGB1 structure solved by NMR spectroscopy (PDB
ID 2YRQ), was used as a starting point for the simulations. As the ﬁrst
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Fig. 2 (continued).
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cessing [26], this amino acid was deleted from the model and only the
region from Gly2 to Arg170 (i.e., BoxA, BoxB, and the connecting loop)
was considered in the MD simulations.
All the investigated HMGB1models (fr- of ds-) were ﬁrst minimized
using the program ALMOST [27]. Then, the TLEAP module of Amber-
Tools16 was used to solvate the protein in a box of water with a mini-
mum distance of 10 Å from the protein surface. The net charge of the
system was neutralized by adding a proper number of ions (17 or 15
Cl− for fr- or ds-HMGB1 respectively). The ff14SB [28] forceﬁeld param-
eters were used to describe the protein, while the TIP3P [29] model and
the parameters proposed by Joung et al. [30] were used for water and
counter ions, respectively. The solvated system was relaxed by a two-
step protocol to remove atomic clashes [31] First, we performed an en-
ergy minimization for 10,000 steps, or until the energy gradient of 0.2
kcal/mol/Åwas reached, restraining the atomic coordinates of backbone
with harmonic potential (k = 20 kcal/mol/Å2). This ﬁrst phase was
followed by an energyminimization for 100,000 steps or until an energy
gradient of 0.0001 kcal/mol/Å was reached, without any restraint. After
minimization, the temperature of the systemwas gradually increased to
300 K over 40 ps under constant volume condition (NVT) constraining
the backbone coordinates in the ﬁrst 20 with a harmonic potential (k
= 20 kcal/mol/Å2). Finally, the system was equilibrated at 300 K for
20 ps under constant pressure conditions (NPT, 1 atm). Pressure and
temperature were maintained constant using the Berendsen barostat
and thermostat, respectively [32]. Electrostatic interactions were
treated with PME [33] with a cutoff of 9 Å. During the calculations, all
bonds involving hydrogen atoms were constrained with the SHAKE
[34] algorithm. All calculations were performed using the PMEMD of
Amber16 code in the GPU accelerated version [35] with a time step
of 2 fs.
Production runs were carried out using the following scheme.
After the ﬁrst simulation of 1 μs, 29 of the saved frames were ran-
domly selected and used as a starting point for 29 additional simula-
tions (see Table 1). The atom velocities were reassigned at the
beginning of each simulation to obtain uncorrelated and indepen-
dent trajectories.2.2. Trajectory Analysis
HMGB1 radius of gyration (RoG) was computed using the cpptraj
[36] module available in AmberTools16 including all the protein resi-
dues. To assess the convergence of RoG calculation, 75,000 snapshots
sampled over the 30 × 1 μs trajectories were divided into six groups of
12,500 snapshot. Then the snapshots belonging to one of the six groups
were excluded from the calculation and the results compared with
those obtained using the full conformation ensemble (Fig. S2).The RMSDs of BoxA (Lys8 to Ile79) and BoxB (Lys96 to Arg163)were
computed with the VMD [37] software, using the ﬁrst conformation
from the HMGB1 NMR bundle (PDB ID code 2YRQ) as a reference.
The solvent accessible surface area (SASA)was computed for the en-
tire protein, BoxA, and BoxB using the LCPO algorithm [38] imple-
mented in the cpptraj module of Amber16.
Finally, atom-atom and residue-residue contact analyses were car-
ried out using the g_contacts program developed by Bau and
Grubmuller [39]. Given that 1H\\1H NOEs are detectable up to a dis-
tance of approximatively 5–6 Å, we used a cut-off of 6 Å in the contacts
analysis.
The contribution of individual residues to the total protein-protein
interaction energy was computed using the MMPBSA.py [40] module
available in Amber16. A total of 900 snapshots were extracted from
the MD simulations of the CXCL122/HMGB1 heterocomplex. Polar con-
tributions to solvation energy were computed with the Onufriev,
Bashford and Casemodel, setting the dielectric constant to 1 for the sol-
ute and 80 for the solvent [41]. Salt concentration was set to 0.2 M.
Nonpolar contributions to the solvation free energies were esti-
mated by a term depending by the solvent-accessible surface area
(SASA) setting γ to a value of 0.0072 kcal/mol/Å2.
2.3. Clustering Procedure
The sampled protein conformations were clustered with the g_clus-
ter (GROMOS method) program available in the GROMACS software
package (version 5.1.2) [41,42]. After several clustering runs (Table
S2) and an accurate visual inspection of the results, we veriﬁed that
the application of an RMSD cutoff of 1.4 nm allowed us to discriminate
different system conformations and to limit the number of singleton
clusters simultaneously.
Twelve and eleven clusters were obtained for fr- and ds-HMGB1, re-
spectively. For both systems, the centers of theﬁrst three clusters,which
in both cases accounted for N90% of the sampled conformations, were
selected for further analysis.
2.4. Docking Procedure
The centers of the three most populated clusters derived from anal-
ysis fr- and ds-HMGB1 MD simulations were then used in docking cal-
culations to obtain the putative structures of the CXCL122/HMGB1
heterocomplex.
For CXCL12, we used the center of themost populated cluster (75.2%
of the sampled structures) obtained by clustering (RMSD cutoff 3.5 Å)
the simulation of 300 ns, carried out starting from the NMR structure
deposited in the PDB databank with the PDBID 2KEC [43]. MD simula-
tions were performed with the same setup and force ﬁeld parameters
54%
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55%
Fig. 3. Representative conformations of the threemost populated clusters (cluster centers)
of fr-HMGB1 (A, C, and E) and ds-HMGB1 (G, I, and K) obtained from the cluster analysis
performed using the GROMOSmethod [55]. The cluster size is reported as a percentage of
the entire conformational ensemble. Structures of the complexes between the three most
representative fr-HMGB1 (B, D, and F) and ds-HMGB1 (H, J, and L) conformations and two
CXCL12 molecules (green) were obtained using protein-protein docking software
HADDOCK.
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cysteine residues at positions 9–34 and 11–50, respectively.
Docking calculations were performed using the HADDOCK 2.2
webserver [44]. These calculations require the user to deﬁne the resi-
dues forming the binding site and, while the residues involved in the in-
teraction between the BoxB and CXCL12 have been identiﬁed by NMR
chemical shift perturbations and reported in our previous study [16],
the residues forming the BoxA binding site have not yet been deﬁned.
Therefore, for BoxA we used ‘homologous’ residues obtained aligning
the structures of both HMGB1 boxes (Table 2). Only the structures of
the complex with the best HADDOCK scores were kept for further
analysis.
2.5. MD Simulations of the CXCL122/HMGB1 Complexes
The structures of the heterocomplex obtained by docking calcula-
tionswere prepared and simulated for 500 nswith the same parameters
and set-up used for HMGB1 and CXCL12.
During the ﬁrst 200 ns, a harmonic distance restraint was applied
between the centers of mass of HMGB1 and CXCL12 to optimize atomic
contacts at the protein-protein interface. In particular, the force con-
stant (k) was slowly decreased from 400 kcal/mol/Å2 to 0 over the
ﬁrst 200 ns. Then the systems were simulated for additional 300 ns. In
order to increase the statistical signiﬁcance of the calculations these
simulations were repeated three times [45].
2.6. Analysis of the Trajectories of the CXCL122/HMGB1 Complexes
The last 300 ns of the MD simulations trajectories computed for the
CXCL122/HMGB1 complexes were ﬁrst visually analyzed to assess the
stability of the complex.
Then the distance between the N-terminal domains of the two
CXCL12 molecules were computed with the aim of determining
whether the obtained CXCL122/HMGB1 complexes conformations
could potentially bind to and activate CXCR4 dimers.
The distance between the two binding sites in the CXCR4 receptor
dimers served as the reference value. This value was determined mea-
suring the distance between the two chemokine N-terminal domains
(Cα of Leu1) in the structure of a CXCR4 receptor (pdb code 4RWS
[46]) in complexwith a CXCL12 analog (viralmacrophage inﬂammatory
protein II (vMIP-II)).
The dimer structure was obtained applying the crystal symmetry to
the deposited structure (Fig. S4).
3. Results and Discussion
3.1. MST Investigations of the CXCL12/HMGB1 Binding
Several experiments demonstrated that only fr-HMGB1 can form a
heterocomplex with CXCL12 enhancing its chemotactic activity, and
that CXCL12 can interacts with both BoxA and BoxB, individually
[16,18].
However, the strength of the binding between these two molecules
in the two oxidation states has never been reported. Therefore, we used
MST experiments to determine the dissociation constant of the
heterocomplex with fr- and ds-HMGB1.
MST is a recently developed biophysical technique enabling the in-
vestigation ofmolecular interactions in liquid phase, i.e. without sample
immobilization, measuring changes in the response to the force of a
temperature gradient upon binding [22,23].
In agreement with previously published data [17], the experiments
conﬁrmed the heterocomplex formation, with an apparent Kd value of
77.4±16 μM(Fig. 2A). Of note, using the same range of CXCL12 concen-
tration, the heterocomplex was not detected in the presence of the ds-
HMGB1 (Fig. 2B), further supporting the speciﬁcity of the fr-HMGB1
for CXCL12 binding.These ﬁndings are in line with recent data obtained by De Leo et al.
[47] which report an apparent Kd for the CXCL12/HMGB1 in the lowmi-
cromolar range.
3.2. HMGB1 MD Simulations
According to experimental observations, only fr-HMGB1 can form a
heterocomplexwith CXCL12, enhancing its chemotactic activity [16,18].
These experimental ﬁndings can be explained by different hypotheses.
Indeed, the making/breaking of the disulﬁde bond can: (1) inﬂuence
the local structure of BoxAmaking it unable to bind CXCL12, (2) induce
a shift of the protein conformational ensemble making the HMGB1 less
suitable to form theheterocomplex or, (3) the observed effect is due to a
combination of the above factors.
The propensity of HMGB1 to form dimers and/or tetramers has been
recently shown by Helmerhorst and co-workers [48–50]. Therefore, its
891E.M.A. Fassi et al. / Computational and Structural Biotechnology Journal 17 (2019) 886–894relevance for the different HMGB1 functions should be accurately
evaluated.
Cell migration experiments [17,20], as well as, MST measurements
were performed at a ﬁxed concentration of HMGB1 signiﬁcantly
below (300 nM or 10 nM) the dimerization value (KD) determined by
SPR experiments (2 μM) [49]. Moreover, in a recent study Raggi et al.
[51] determined an average concentration of HMGB1 in synovial ﬂuids
of individuals affected by oligo articular juvenile idiopathic arthritis of
2 nM. [51] From this, we can conclude that only a negligible fraction
of HMGB1 is in dimeric form in the experimental conditions where
the CXCL12/HMGB1 heterocomplex effect has been observed. There-
fore, we simulated both the systems (fr- and ds-HMGB1) for 30 μs MD
considering only the monomeric form of the protein.
The simulations outputswere analyzed focusing on descriptors such
as the radius of gyration (RoG, Fig. 2C), the solvent accessible surface
area (SASA, Fig. 2D) and the RMSD with respect to NMR structure
(PDB ID code 2YRQ, Fig. S1), adequate to recapitulate the features of
the protein conformational space.
NMR studies on ds-HMGB1, performed by Wang et al. [52] highli-
ghted a set of 1H\\1H NOE signals due to the interaction of Phe38
with Val20, Gln21, and Arg24 not detected for fr-HMGB1. As a conse-
quence, a different orientation is assumed by Phe38 in the available
HMGB1 structure (pdb codes: 2YRQ and 2RTU, Fig. 2E-F).
Therefore, we focused our attention also on descriptors (distances,
residue-residue, and atom-atom contacts) capable to capture the differ-
ences in the structure and dynamics of this region in the two different
oxidation states (Fig. 2G–I and Table S1).
RMSD analysis of BoxA (Fig. S1C) resulted in very similar values for
both ds-HMGB1 and fr-HMGB1, indicating that the formation of the
Cys23-Cys45 disulﬁde bond in BoxA does not strongly alter the local
conformation.
Concerning the Phe38 orientation, considering that 1H\\1H NOE
signals origin by short range interactions (b 5–6 Å), we monitored
both the distribution of the distances between the center of mass
Phe38 and the three interacting residues indicated by the NMR experi-
ments (Val20, Gln21 and Arg24) and the percentage of the simulation
time in which the atom-atom contacts responsible for the 1H\\1H
NOE signals are present (Table S1).
This analysis (Fig. 2G, H, I and Table S1) conﬁrmed that the presence
of the disulﬁde bond facilitates the interaction of Phe38 with Val20,
Gln21 and Arg24 however, the results of both residue-residue distance
analyses and atom-atom contacts suggest that, in agreement with the
dynamical nature of the system, Phe38 can ﬂip between different con-
formation in both fr- and ds-HMGB1.
The RoG analysis (Fig. 2C) showed a difference between the confor-
mational spaces visited by the two systems. While two separate peaks
are visible for fr-HMGB1 (the ﬁrst centered at ~24 Å and the second at
~34 Å), only the ﬁrst peak is clearly visible for ds-HMGB1. Based on
this observation, the system containing the disulﬁde bond more fre-
quently assumes a compact conformation than fr-HMGB1.
Finally, the SASAs for the entire protein (Fig. 2D) and for BoxA and
BoxB (Fig. S1A\\B), were estimated to evaluate the propensity of the
two different HMGB1 forms to bind CXCL12. In all cases, we obtained
a lower value for ds-HMGB1 than fr-HMGB1.
Summarizing, all the analyses of the simulations indicate that the
presence or absence of the disulﬁde bond modulates the protein sizeTable 3
Percentage of the frames sampled in the MD simulations in which the two HMGB1 do-
mains (BoxA and BoxB) or the two N-terminal domains of CXCL12 have the same
orientation.
fr-HMGB1(I) fr-HMGB1(II) ds-HMGB1(II)
Domains 94% Domains 100% Domains 0%
NT-ends 61% NT-ends 92% NT-ends 0%and the reciprocal orientation of both the boxes and the SASA of
HMGB1 without signiﬁcantly altering the structure of BoxA and BoxB.
As a consequence, a change in the conformational space explored by
ds- or fr-HMGB1 seems to be themolecular determinant of the reduced
fr-HMGB1 propensity to form a complex with two CXCL12 molecules
reported in experimental studies [16–18].
3.3. CXCL122-HMGB1 Binding
To further investigate the propensity of the twoHMGB1 redox states
to bind CXCL12, protein-protein docking studies were performed. Rep-
resentative structures were selected from the protein ensembles ob-
tained by MD simulations by cluster analysis.
In the case of fr-HMGB1, the two most populated clusters (Fig. 3A
andC) include55% and20% of the conformations sampled by the system
during MD simulations. Importantly, in both cluster center structures,
the two CXCL12 binding sites are free (i.e., not interacting with other
protein regions) and potentially able to bind CXCL12, with the N-
terminal domain oriented in the same direction.
In contrast, the representative conformation (cluster center, Fig. 3E)
from the third cluster, which comprises the 14% of the generated con-
formational ensemble, is more compact, with the two domains inter-
acting and, consequently, unable to bind CXCL12.
For ds-HMGB1, we observed an almost reversed trend. In this case,
the ﬁrst and the third most populated clusters (Fig. 3G and K) contain
54% and 13% of the conformations, respectively. Interestingly, in both
cluster centers, BoxA and BoxB are involved in reciprocal interactions
that signiﬁcantly limit or nullify their abilities to bind one or more
CXCL12 molecules.
Only the representative conformation (center cluster) from the sec-
ond cluster (Fig. 3I), which accounts for 25% of the total conformations,
is expanded and both domains are available to bind one CXCL12
molecule.
In summary, considering the entire conformational ensemble of fr-
and ds-HMGB1 sampled during 30 μs of MD simulations, we can esti-
mate that while the ~75% of the conformations assumed by fr-HMGB1
can activate the CXCR4 dimers, only ~25% of the observed ds-HMGB1
conformation can do the same.
Docking calculations were performed to investigate which of the
cluster centers were able to bind two CXCL12molecules and obtain pu-
tative structures of the CXCL12/HMGB1 heterocomplexes (Fig. 3B, D, F,
H, J, and L). These calculations conﬁrmed our ﬁndings from the analysis
of the MD simulations trajectories. In particular, CXCL12 could be
docked in the correct binding site only in the two center structures
from the ﬁrst two clusters from the simulations of fr-HMGB1 (fr-
HMGB1(I) and fr-HMGB1(II)). Moreover, in this case, the two N-termi-
nals domains of CXCL12, crucial for CXCR4 triggering [53], are oriented
in the same direction, and the resulting heterocomplexes have an opti-
mal conformation to bind a CXCR4 dimer. In contrast, the third cluster
center structure fr-HMGB1 (III) is unable to bind two CXCL12molecules
due to the inaccessibility of BoxA.
In the case of ds-HMGB1, the docking of two chemokines in the cor-
rect binding sitewas only possiblewith the structure of the second clus-
ter center. However, a visual inspection of the resulting complex
(Fig. 3J) reveals that the N-terminal domains of the two CXCL12 are
not oriented in the same direction, making impossible the activation
of CXCR4 dimers.
Docking calculations were performed using static structures, thus
completely neglecting protein dynamics and the reciprocal induced ﬁt
effects. Therefore, aiming to explore the stability of the complexes ob-
tained by docking, we simulated them for 500 ns. It should be noted
that these simulations were not performed to fully explore the confor-
mational ensemble of the complex, but to relax the system and obtain
more reliable models.
The simulations were analyzed with a focus on the following fea-
tures: (1) orientations of both binding sites for CXCL12, (2) orientations
Table 4
Distance between K1 of the two CXCL12 molecules in complex with HMGB1 measured
during MD simulations. The distance was only measured in simulations in which the
two N-terminal domains are properly oriented to trigger CXCR4 dimers.
Distance between K1 of CXCL122 molecules (Ref. = 44.0 Å)
Sim 1 Sim 2 Sim 3
fr-HMGB1(I) – 44.66 ± 14.57 Å 48.66 ± 15.03 Å
fr-HMGB1(II) 53.25 ± 15.40 Å 56.42 ± 10.81 Å 48.88 ± 13.03 Å
ds-HMGB1(II) – – –
892 E.M.A. Fassi et al. / Computational and Structural Biotechnology Journal 17 (2019) 886–894of theN-terminal domains of the twoCXCL12molecules and (3) stability
of the complex (Table 3).
The analysis of the MD simulations for fr-HMGB1(I) revealed that
both domains are optimally oriented on the same side while the N-
terminal domains are correctly oriented in the 61% of the analyzed
conformations.
In fr-HMGB1(II) MD simulations, both domains and the N-terminal
domains of CXCL12 were oriented in the same direction essentially for
all the simulation time.
On the contrary, during theMD simulations of ds-HMGB1(II), which
is the only conformation of the oxidized protein that can accommodate
two CXCL12 molecules, both domains and the N-terminal of CXCL12
were oriented in opposite directions. Furthermore, the protein tended
to assume conformations in which BoxA and BoxB are close to each
other. Therefore, the protein conformation is more compact (Fig. S3).
In order to better assess the ability of the various heterocomplexes to
trigger CXCR4 dimers,we determined the optimal distance between the
CXCL12 N-terminal domains (44 Å, Fig. S4) analyzing the X-ray struc-
ture of the CXCR4 dimer in complex with a viral chemokine (PDB ID
code 4RWS [46], see methods). This value was then compared with
the average distances measured in the MD simulations (Table 4).
For the fr-HMGB1(I) simulations the measured average value was
approximatively 44.0 Å, while for the fr-HMGB1(II) simulations, the
resulting value was larger than the reference value. However, a morefr-HMGB1 (I)
fr-HMGB1 (II
ds-HMGB1 (I)
ds-HMGB1
Fig. 4. Graphical summary of the results, the blue arrow indicates thaccurate analysis of the simulations showed that the N-terminal do-
mains stay at the proper distance during 2/3 of the simulation time.
In summary, MD simulations performed on the complexes obtained
using molecular docking lead to some interesting observations. In fact,
while fr-HMGB1 forms stable heterocomplexes with theN-terminal do-
mains of CXCL12 optimally oriented for most of the time, all complexes
betweenCXCL12 and ds-HMGB1, sampled in our simulations, are unsta-
ble and tend to assume conformations which are not competent for the
binding to CXCR4 dimers.
Lastly, aimed to determine the key interactions for the formation of
fr-HMGB1(I) and (II) which emerged as potentially able to trigger a
CXCR4 dimer, we computed the contribution of single residues to the
protein-protein interaction energy by MM-GBSA effective binding en-
ergy decomposition (Table S4) [54].
This analysis highlighted the key role played by Phe38 in the forma-
tion of the heterocomplex with both fr-HMGB1(I) and (II) forms and in-
dicated aweaker interaction betweenCXCL12 andBoxB in fr-HMGB1(II).
4. Conclusions
Computational studies conducted on the two redox states of HMGB1
highlighted signiﬁcant differences in the conformations adopted by the
fr-HMGB1 and the ds-HMGB1 forms. In particular, RoG and SASA values
computed for ds-HMGB1 were signiﬁcantly lower than those of fr-
HMGB1, indicating that the oxidized form of HMGB1 is more compact
than the reduced one, while the local structure of BoxA remained essen-
tially unchanged over 30 μs of MD simulations.
Cluster analysis and docking calculations provided insights into the
molecular determinants underlying the enhancement of CXCR4 activa-
tion induced by the heterocomplex. In fact, the analysis of these struc-
tures showed that the ~75% of the conformations of fr-HMGB1 have
BoxA and BoxB accessible for the binding of CXCL12. Furthermore, in
these structures the two domains are optimally oriented to form
CXCL122/HMGB1 heterocomplexes competent to bind and trigger
CXCR4 dimers (Fig. 4).)
fr-HMGB1 (III)
ds-HMGB1 (III)
 (II)
at the corresponding heterocomplex can bind a CXCR4 dimer.
893E.M.A. Fassi et al. / Computational and Structural Biotechnology Journal 17 (2019) 886–894In conclusion, our computational studies support the hypothesis
that the absence/presence of the disulﬁde bond in BoxA of HMGB1, reg-
ulates the formation of CXCL12/HMGB1 heterocomplex and the en-
hancement of CXCR4 signaling by the modulation of the HMGB1
conformational landscape.
Furthermore, even thaking into account the intrinsic limitations of
MD simulations, such as the force ﬁeld accuracy, the simpliﬁed repre-
sentation of the bulk and the limited conformational sampling, the re-
sults of our study provide better understanding of the CXCL122/
HMGB1 heterocomplex mode of action paving the way to the design
of molecules capable to interfere with the CXCL12/HMGB1 heterocom-
plex functions.
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